https://www.actymthera.com/news/poster%3A-sitc-2022-%E2%80%93-37th-annual-sitc-meeting-%E2%80%93-nov-8-12-2022%2C-boston%2C-ma 2025-06-03 https://www.actymthera.com/news/actym-therapeutics-and-wacker-biotech-sign-manufacturing-contract-for-actym%E2%80%99s-lead-candidate-for-the-treatment-of-solid-tumors 2025-06-03 https://www.actymthera.com/news/actym-therapeutics-ceo-dr.-christopher-thanos-named-one-of-the-%E2%80%9Ctop-25-biotech-ceos-of-2022%E2%80%9D 2025-06-03 https://www.actymthera.com/news/actym-therapeutics-announces-issuance-of-us-patent 2025-06-03 https://www.actymthera.com/news/actym-therapeutics-announces-lead-candidate-for-clinical-development%2C-presentation-at-sitc 2025-06-03 https://www.actymthera.com/news/actym-therapeutics%2C-inc.-today-announced-the-appointment-of-chan-whiting%2C-ph.d.-as-chief-development-officer 2025-06-03 https://www.actymthera.com/news/actym-to-present-at-the-sting-%26-tlr-targeting-therapies-digital-summit%2C-may-26%2C-2021 2025-06-03 https://www.actymthera.com/news/actym-therapeutics-announces-expansion-of-scientific-advisory-board 2025-06-03 https://www.actymthera.com/news/actym-therapeutics-raises-%2434-million-series-a 2025-06-03 https://www.actymthera.com/news/actym-therapeutics-will-present-data-at-the-2019-society-for-the-immunotherapy-of-cancer-(sitc)-annual-meeting 2025-06-03 https://www.actymthera.com/news/actym-to-present-at-the-pegs-annual-summit%2C-boston%2C-ma%2C-usa-april-12%2C-2019 2025-06-03 https://www.actymthera.com/news/actym-therapeutics-will-present-data-at-the-2019-american-association-for-cancer-research-annual-meeting 2025-06-03 https://www.actymthera.com/news/actym-therapeutics-will-present-data-at-the-2018-society-for-immunotherapy-of-cancer-(sitc)-annual-meeting 2025-06-03 https://www.actymthera.com/news/https%3A%2F%2Factymthera.com%2Factym-therapeutics-announces-participation-in-may-investor-conferences%2F 2025-06-03 https://www.actymthera.com/news/actym-therapeutics-announces-significant-expansion-of-senior-leadership 2025-06-03 https://www.actymthera.com/news/actym-therapeutics-reports-preclinical-data-demonstrating-actm-838%E2%80%99s-ability-to-generate-anti-tumor-immunity 2025-06-03 https://www.actymthera.com/news/actym-therapeutics-selected-as-part-of-the-biocentury-bayhelix-east-west-summit-class-of-2022 2025-06-03 https://www.actymthera.com/news/actym-to-present-at-the-oncolytic-viruses%2F-non-viral-gene-therapy-delivery-digital-conference-on-dec-1%2C-2022 2025-06-03 https://www.actymthera.com/news/actym-therapeutics-reports-data-at-aacr-demonstrating-tumor-specific-payload-expression-from-actm-838-in-preclinical-models 2025-06-03 https://www.actymthera.com/news/poster%3A-aacr-2023-%E2%80%93-aacr-annual-meeting-%E2%80%93-april-14-19-2023%2C-orlando%2C-fl 2025-06-03 https://www.actymthera.com/news/biocentury-bayhelix-east-west-biopharma-summit-%E2%80%93-october-2-4%2C-2023 2025-06-03 https://www.actymthera.com/news/bio-investor-forum-%E2%80%93-october-17-18%2C-2023 2025-06-03 https://www.actymthera.com/news/society-for-immunotherapy-of-cancer-38th-annual-meeting-%E2%80%93-november-1-5%2C-2023 2025-06-03 https://www.actymthera.com/news/actym-closes-%2459.5-million-series-a-with-new-%2425.5-million-extension 2025-06-03 https://www.actymthera.com/news/actym-appoints-steven-vicik-as-chief-technical-officer 2025-06-03 https://www.actymthera.com/news/actym-to-present-preclinical-data-on-clinical-candidate-actm-838-at-38th-sitc-annual-meeting 2025-06-03 https://www.actymthera.com/news/poster%3A-sitc-2023-%E2%80%93-38th-annual-sitc-meeting-%E2%80%93-nov-1-5-2023%2C-san-diego%2C-ca 2025-06-03 https://www.actymthera.com/news/poster%3A-aacr-(american-association-for-cancer-research)%2C-april-5-10%2C-2024%2C-san-diego-ca 2025-06-03 https://www.actymthera.com/news/actym-therapeutics-appoints-thomas-smart-as-ceo 2025-06-03 https://www.actymthera.com/news/actym-therapeutics-expands-management-team-with-key-appointments-to-build-product-pipeline-and-advance-clinical-development-strategies 2025-06-03 https://www.actymthera.com/news/actym-therapeutics-announces-ind-clearance-for-phase-1-clinical-trial-investigating-lead-program-actm-838-in-patients-with-solid-tumors 2025-06-03